Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors

16 May 2011

Abstract excerpt

Asfar S. Azmi 1 , Sanjeev Banerjee 1 , Shadan Ali 1 , Zhiwei Wang 1 , Bin Bao 1 , Frances W.J. Beck 2 , Main Maitah 2 , Minsig Choi 2 , Tony F. Shields 2 , Philip A. Philip 2 , Fazlul H. Sarkar 1 , Ramzi M. Mohammad 2 1 Department of Pathology, Wayne State University School of Medicine 2 Departments of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan Keywords: MDM2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bioinformatics and Genomic Networks
Share to Cancer-related Molecular Pathways
Share to Epigenetics and DNA Methylation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21623005
DOI: 10.18632/oncotarget.269

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumorsPMID 21623005Read ↗

Network integration of multi-tumour omics data suggests novel targeting strategiesSemantic proximity Read ↗

Network integration of multi-tumour omics data suggests novel targeting strategiesSemantic proximity Read ↗

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.Semantic proximity Read ↗

Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.Semantic proximity Read ↗

Molecular Landscape of TP53/RB1 Co-Altered Tumors Uncovers Emerging Therapeutic Vulnerabilities.Semantic proximity Read ↗

Functional synergies yet distinct modulators affected by genetic alterations in common human cancers.Semantic proximity Read ↗

Drug and disease signature integration identifies synergistic combinations in glioblastomaSemantic proximity Read ↗

Systematic identification of combinatorial drivers and targets in cancer cell lines.Semantic proximity Read ↗

Anticancer Target Combinations: Network-Informed Signaling-Based Approach to DiscoverySemantic proximity Read ↗

MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathwaysSemantic proximity Read ↗

Identifying Modules of Cooperating Cancer DriversSemantic proximity Read ↗

Repurposing proteasome inhibitors in the treatment of esophageal squamous cell cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.